Week 2 (Quiz 2) Flashcards

1
Q

Ligand

A

substance that binds a receptor (often reversible)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Receptor

A

protein that interacts with a ligand to initiate a physiologic response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

______ allows for signal amplification, coordination of multiple processes from single stimulus and precise regulation of cellular events.

A

Signal transduction cascade.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Emax

A

maximum efficacy of a drug, all receptors are bound.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

E1/2

A

half of the maximum response, used to find the ED50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ED50

A

effective dose or effective concentration eliciting

half of the maximum response; a measure of drug potency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

More potent drug has a ___ ED50

A

lower (less drug is

needed to elicit half of the maximum response)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Threshold dose

A

dose at which the drug starts eliciting a response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Maximal Effective Dose

A

dose required for a maximal response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Therapeutic Index equation

A

LD50/ED50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

LD50 (lethal dose)

A

Concentration at which 50% of subjects will die

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Higher therapeutic index means

A

the ED50 and LD50 are

farther apart = “safer” drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

PCN has a high or low TI

A

high!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Coumadin, Digoxin, Chemo have a high or low TI

A

low! — more dangerous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Therapeutic Window

A

concentration range that elicits response

w/o unwanted side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Agonists

A

elicit response from receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Full agonist

A

elicits max response (curves 1 and 2 on graphs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Partial agonist

A

elicits partial response, will never reach max

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Antagonists

A

bind receptor but don’t induce response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Competitive antagonists bind:

A

Ligand-binding site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Competitive antagonists _____ ED50

A

Increase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Competitive antagonists shift curve _____

A

right

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Competitive antagonists _____ Emax

A

Do not alter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Competitive antagonists (potency and efficacy)

A

decreases potency, efficacy remains the same.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Non-competitive antagonists bind:

A

receptor away from ligand-binding site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

NC antagonists ____ Emax

A

decreases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Drug dose and NC antagonists

A

Cannot be overcome by increasing dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Spare receptors

A

when drug achieves max response without using all available receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Desensitization

A

repeated/continuous dose that alters (usually decreases) responsiveness of receptor to drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Ligand-gated ion channels

A

Ligand-binding causes channel to open; Fastest acting (milliseconds)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

2 examples of ligand-gated ion channels

A

Nicotinic receptor (Ach) – allows sodium to enter cell -> depolarizes

GABA (y-aminobutyric acid) – allows chlorine to enter cell -> hyperpolarizes

32
Q

G-protein coupled receptors

A

Largest family of proteins in body; largest receptor and therapeutic target class; response in seconds
Ligand binds –> inactive (GDP bound) G-protein loses GDP and binds GTP –> α-GTP (active) dissociates from βγ
and receptor

33
Q

Structure of G-protein coupled receptors

A

7 TM domains, heterotrimeric G-protein (3 domains aby)

34
Q

The alpha subunits of the GPCR are

A

the main effector, bind GTP

35
Q

Gs

A

promotes adenylyl cyclase –> ATP to cAMP –> activates PKA –> phosphorylates proteins like
RyR2 –> increase intracellular calcium (muscle contraction)

36
Q

Types of Gs subunits

A

“Big Boys Don’t Have Vaginas” β-adrenergic1,

β-adrenergic2, Dopamine1, Histamine2, Vasopressin2

37
Q

Gi

A

inhibits adenylyl cyclase –> no activation of PKA

38
Q

Gi receptor types

A

“MAD 2s” - Muscarinic2, α-adrenergic2, Dopamine2, (Muscarinic4) [also
Histamine3 and Histamine4]

39
Q

What is the M2 receptor responsible for?

A
for shaving-induce bradycardia via activation of βγ subunit activating
potassium channels (see next page for ions and action potential)
40
Q

Gq

A

activates phospholipase C –> cleaves PIP2 into DAG and IP3 –> DAG activates PKC and arachidonic
acid; IP3 increases intracellular calcium

41
Q

Gq receptor types

A

“Gq HAVE 1 M&M” - Histamine1, α-adrenergic1, Vasopressin1,
Muscarinic1, Muscarinic3, (Muscarinic5)

42
Q

By subunit

A

ion channel regulation i.e. potassium channels

43
Q

Kinase-linked receptors

A

Heterogeneous group that signals through enzymatic cascade (hours)

44
Q

Kinase-linked receptors structure

A

Single helical TM domain connecting receptor and kinase domains

45
Q

Kinase-linked receptors mechanism

A

bind ligand –> receptors dimerize –> auto-phosphorylation –> phosphorylation binding protein (PbP) binds
kinase domains and initiates signal

46
Q

Growth Factor (EGF) (Kinase-linked receptor)

A

Grb2 (SH2 domain) binds kinase and is phosphorylated –> Ras –> Raf –> Mek –> Erk –> to
nucleus to phosphorylate transcription factors which turn genes on

47
Q

Cytokine (IL1) (Kinase-linked receptor)

A

Jak binds kinase domain, Stat binds kinase domain, is phosphorylated –> Stat dimerizes, moves to
nucleus and activates transcription

48
Q

Nuclear receptors

A

non-membrane proteins (in cytosol or nucleus) that interact directly with DNA upon ligand binding (no
transduction cascade); take hours

49
Q

2 Examples of Nuclear Receptors

A

Thyroid hormone receptor

and estrogen receptor

50
Q

Estrogen receptor and Tamoxifen

A

Tamoxifen (drug for breast cancer) binds ERα and competes with estrogen which normally
creates complex that activates genes that promote breast cancer cell growth and division

51
Q

Main cation inside the cell

A

Potassium; will efflux when channels are open (repolarize)

52
Q

Main cation outside of cell

A

Sodium; will influx when channels are open (depolarize)

53
Q

Divalent cation outside of cell

A

Calcium; will influx when channels are open

54
Q

Anion outside of the cell

55
Q

Eca

56
Q

Ena

57
Q

Ek

58
Q

Nerst equation

A

Es = 27ln ([S] outside)/([S] inside)

59
Q

Time 0 in the action potential

A

Rapid depolarization: rapid sodium
channels open in response to stimulus (i.e.
nicotinic receptor); membrane depolarizes
to about +47 mV

60
Q

What happens if the cell resting potential is higher than -96 mV?

A

if cell resting potential is higher
than -96mV the cell is less excitable,
because some fast channels will be
inactivated

61
Q

Time 1 in the action potential

A
Inactivation of fast sodium channels;
transient outward potassium channels
open (chlorine also goes out); small
downward deflection of membrane
potential
62
Q

Time 2 in the action potential

A

Plateau phase: L-type calcium channels
open, balancing out the flow through slow
delayed rectifier potassium channels

63
Q

Time 3 in the action potential

A
Rapid Repolarization: L-type calcium
channels close; Slow delayed rectifier
potassium channels remain open; voltage
sensitive rapid delayed rectifier potassium
channels and inwardly rectifying
potassium current are open
64
Q

Time 4 in the action potential

A

resting membrane potential: KI (inward
rectifying current); potassium channels
keep membrane repolarize

65
Q

Effects of activating potassium channels

A

increases repolarization, prevents contraction (i.e. vasodilation, shaving induced bradycardia)

66
Q

Effects of inactivating potassium channels

A

decreases repolarization, prolongs action potential

67
Q

Effects of activating calcum or sodium channels

A

promotes depolarization

68
Q

What is torsades de pointes?

A

French for “twisting of the points”; rare variety of ventricular tachycardia where the ECG demonstrates polymorphic ventricular
tachycardia and the illusion that the QRS complex is twisting around isoelectric baseline.

69
Q

What can tosades de pointes cause?

A

Can cause drop in BP, seizures, and syncope and degenerate into VF –> sudden cardiac death

70
Q

What is long QT syndrome?

A

delayed repolarization of heart following a heartbeat - increased risk of
torsades (involves a K+ channels) –> causes differences in refractory period of
myocytes –> arrhythmias

71
Q

What can cause early after-depolarizations?

A

L-type calcium channels (open during plateau phase)

72
Q

When are people with long QT syndrome at increase risk for death?

A

adrenergic states (stress or excitement)

73
Q

Long CT syndrome can be ____ or ____

A

genetic or drug induced

74
Q

Drug induced long QT syndrome

A
Drug binds (to inner mouth) and inactivates HERG ion
channel responsible for Ikr (K rapid delayed rectifying
current responsible for rapid repolarization of membrane)
75
Q

Genetic long QT syndrome

A

Various polymorphisms that a pt can have, corresponding to a different type of LQTS (LQT1, LQT2. . ., etc.)
About 10% people have a mutation –> genetically predisposed to LQTS

76
Q

Which population have SCN5A Y1102 polymorphism?

A

African American